Healthpoint, DFB To Pay $48M To End FCA Drug Suit

Law360, New York (December 6, 2012, 4:03 PM EST) -- Healthpoint Ltd. and DFB Pharmaceuticals Inc. will pay $48 million as part of a settlement agreement that ended allegations that Healthpoint submitted false claims to Medicare and Medicaid for an unapproved prescription skin ointment, the U.S. Department of Justice said Thursday.

The DOJ said that in January 2011, it intervened in a False Claims Act case against Texas-based Healthpoint, a subsidiary of DFB, alleging the company launched Xenaderm, a prescription skin ointment used for treating nursing home patients' bedsores, without any approval from the U.S. Food...
To view the full article, register now.



Case Information

Case Title

United States, ex rel v. Actavis Mid-Atlantic, et al

Case Number




Nature of Suit

Other Statutory Actions


Rya W. Zobel

Date Filed

August 29, 2002

Law Firms


Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.